NCT04170348View on ClinicalTrials.gov

Daily Vitamin D for Sickle-cell Respiratory Complications

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

June 18, 2024

Study Completion Date

June 18, 2024

Conditions
Sickle Cell DiseaseAnemia, Sickle CellAnemia, Hemolytic, CongenitalRespiratory Tract DiseasesRespiration DisordersAcute Chest SyndromeLung DiseasesAsthmaRespiratory Tract InfectionsNutrition DisordersDeficiency Diseases VitaminVitamin D Deficiency
Interventions
DRUG

Daily oral vitamin D3, 3,333 IU

Oral vitamin D3, 3,333 IU, will be administered daily.

DRUG

Monthly oral vitamin D3, 100,000 IU

Oral vitamin D3, 100,000 IU, will be administered monthly.

DRUG

Placebo oral tablet

Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

lead

Columbia University

OTHER

NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications | Biotech Hunter | Biotech Hunter